𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Erythema nodosum caused by the administration of granulocyte colony-stimulating factor in a patient with refractory anemia

✍ Scribed by Jun Nomiyama; Kenji Shinohara; Hirofumi Inque

Publisher
John Wiley and Sons
Year
1994
Tongue
English
Weight
262 KB
Volume
47
Category
Article
ISSN
0361-8609

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A phase I trial of ifosfamide and paclit
A phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors
✍ Craig A. Bunnell; Lynn Thompson; Lori Buswell; Ross Berkowitz; Michael Muto; Ell πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 75 KB πŸ‘ 2 views

## Background: Ifosfamide and paclitaxel are antineoplastic agents with broad activity and with different mechanisms of action. a phase i trial was conducted to determine the maximum tolerated dose and associated toxicities of these agents when used in combination. ## Methods: Patients with refra

Eosinophilia resulting from administrati
Eosinophilia resulting from administration of recombinant granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in a patient with T-Ξ³ lymphoproliferative disease
✍ R. Gonzales-Chambers; Dr. C. Rosenfeld; A. Winkelstein; L. Dameshek πŸ“‚ Article πŸ“… 1991 πŸ› John Wiley and Sons 🌐 English βš– 217 KB πŸ‘ 2 views

A therapeutic trial of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) was attempted in a patient with neutropenia and frequent infections secondary to T-y lymphoproliferative disease (T-y LPD). During the 14 days of subcutaneous rhGM-CSF (500 kg/m2/day), the absolute e

Phase I trial of paclitaxel, carboplatin
Phase I trial of paclitaxel, carboplatin, and topotecan with or without filgrastim (granulocyte-colony stimulating factor) in the treatment of patients with advanced, refractory cancer
✍ John D. Hainsworth; Howard A. Burris III; Lisa H. Morrissey; F. Anthony Greco πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 72 KB πŸ‘ 2 views

## Background: Topotecan is a new antineoplastic agent with a broad spectrum of activity. the purpose of this phase i trial was to define the maximum tolerated dose of topotecan when added to the widely used combination of paclitaxel and carboplatin. ## Methods: Patients with advanced cancer that

A multicenter randomized phase II trial
A multicenter randomized phase II trial of granulocyte-colony stimulating factor-supported, platinum-based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma
✍ Manuel Hidalgo; CΓ©sar Mendiola; JosΓ© Manuel LΓ³pez-Vega; Daniel Castellano; Migue πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 84 KB πŸ‘ 2 views

The purpose of this study was to analyze whether the addition of granulocyte-colony stimulating factor (G-CSF) to platinum-based combination chemotherapy could increase platinum dose intensity and response rates and decrease hematologic toxicity in patients with advanced epithelial ovarian carcinoma

A phase I clinical and pharmacologic stu
A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma
✍ Hiroaki Okamoto; Akira Nagatomo; Hideo Kunitoh; Hiroshi Kunikane; Koshiro Watana πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 84 KB πŸ‘ 2 views

BACKGROUND. This Phase I study was designed to determine the toxicity and efficacy of a carboplatin and irinotecan (CPT-11) regimen with recombinant human granulocyte colony-stimulating factor (rhG-CSF) support for patients with advanced nonsmall cell lung carcinoma. ## METHODS. Treatment consist